P-FVIII-101

P-FVIII-101 is a liver-directed gene therapy developed for the treatment of Hemophilia A, a genetic bleeding disorder caused by deficiency in coagulation Factor VIII. The therapy utilizes Poseida Therapeutics' proprietary non-viral piggyBac DNA integration system delivered via lipid nanoparticle technology. This approach enables stable and durable integration of the therapeutic transgene into the genome of liver cells, resulting in sustained production of functional human Factor VIII protein. Unlike traditional adeno-associated virus (AAV) gene therapies, P-FVIII-101's nonviral delivery avoids pre-existing immunity issues and allows for potential re-dosing and use in pediatric populations. Preclinical studies have demonstrated that a single dose can achieve normalized (>50%) Factor VIII activity with durable responses observed over several months in animal models[1][4][5][7]. The platform offers advantages such as increased cargo capacity, reduced immunogenicity, lower risk of insertional mutagenesis due to low vector copy numbers per cell, and potentially simpler manufacturing processes[1][8]. Developed by Poseida Therapeutics in partnership with Takeda for clinical development.